Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies

Clinical Cancer Research

Volumn 3, Issue 8, 1997, Pages 1253-1260

  Lamborn, Kathleen R ^a   DeNardo, Gerald L ^b,d   DeNardo, Sally J ^b   Goldstein, Desiree S ^b   Shen, Sui ^b   Larkin, Edward C ^c   Kroger, Linda A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER 67; IMMUNOGLOBULIN ANTIBODY; IODINE 131; LYMPHOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DOSIMETRY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HALF LIFE TIME; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, HETEROPHILE; ANTIBODIES, MONOCLONAL; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; IODINE RADIOISOTOPES; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ORGANOMETALLIC COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0030791487     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bastion, Y., Berger, F., Byron, P., Felman, P., Ffrench, M., and Coiffer, B. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann. Oncol., 2 (Suppl.): 123-129, 1991.
2. Coiffer, B., Gisselbrecht, C., Vose, J., Tilly, H., Herbrecht, R., Bosly, A., and Armitage, J. Prognostic factors in aggressive malignant lymphoma: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J. Clin. Oncol., 9: 211-219, 1991.
3. Cowan, R., Jones, M., Harris, M., Steward, W., Radford, R., Wagstaff, J., Deakin, D., and Crowther, D. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br. J. Cancer, 59: 276-282, 1989.
4. Jagannath, S., Velasquez, W., Tucker, S., Fuller, L., McLaughlin, P., Manny, J., North, L., and Cabanillas, F. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J. Clin. Oncol., 4: 859-865, 1986.
5. Kaminski, M., Coleman, C., Colby, T., Cox, R., and Rosenberg, S. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann. Intern. Med., 104: 747-756, 1986.
6. Shipp, M., Harrington, D., Klatt, M., Jochelson, M., Pinkus, G., Marshall, J., Rosenthal, D., Skarin, A., and Canellos, G. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann. Intern. Med., 104: 757-765, 1986.
7. Shipp, M., Harrington, D., Anderson, J., Armitage, J., Bonadonna, G., Brittinger, G., Cabanillas, F., Canellos, G., Coiffer, B., Connors, J., Cowan, D., Crowther, D., Dahlberg, S., Engelhard, M., Fisher, R., Gisselbrecht, C., Horning, S., Lepage, E., Lister, A., Meerwaldt, J., Montserrat, E., Nissen, N., Oken, M., Peterson, B., Tondini, C., Velasquez, W., and Yeap, B. A predictive model for aggressive NHL: the international non-Hodgkin's lymphoma prognostic factors project. N. Engl. J. Med., 329: 987-994, 1993.
8. Fisher, R., Gaynor, E., Dahlberg, S., Oken, M., Grogan, T., Mize, E., Glick, J., Coltman, C., and Miller, T. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med., 328: 1002-1006, 1993.
9. McMaster, M., Greer, J., Wolff, S., Johnson, D., Greco, F., Mize, E., Stein, R., Lousar, J., Flexner, J., and Hainsworth, J. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma. Cancer (Phila.), 68: 233-241, 1991.
10. Shipp, M., Yeap, B., Harrington, D., Klatt, M., Pinkus, G., Jochelson, M., Rosenthal, D., Skarin, A., and Canellos, G. The M-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J. Clin. Oncol., 8: 84-93, 1990.
11. DeNardo, G., Lamborn, K., DeNardo, S., Goldstein, D., Dolber-Smith, E., Kroger, L., Larkin, E., and Shen, S. Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. Cancer Res., 55 (Suppl.): 5893-5898, 1995.
12. 67Cu-2IT-BAT-Lym-1 and opportunities for improvement. In: D. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 217-227. Boca Raton: CRC Press, Inc., 1995.
13. DeNardo, S., DeNardo, G., O'Grady, L., Macey, D., Mills, S., Epstein, A., Peng, J., and McGahan, J. Treatment of a patient with B-cell lymphoma by 1-131 Lym-1 monoclonal antibodies. Int. J. Biol. Markers, 2: 49-53, 1987.
14. DeNardo, S., DeNardo, G., O'Grady, L., Levy, N., Mills, S., Macey, D., McGahan, J., Miller, C., and Epstein, A. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antib. Immunoconjug. Radiopharm., 1: 17-33, 1988.
15. DeNardo, G., Lewis, J., DeNardo, S., and O'Grady, L. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer (Phila.), 73: 1425-1432, 1994.
16. Lewis, J., DeNardo, G., and DeNardo, S. Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma, 14: 115-120, 1995.
17. DeNardo, G., Mirick, G., Kroger, L., Lamborn, K., and DeNardo, S. HAMA response after a series of injections of Lym-1 monoclonal antibody in patients with B-lymphocytic malignancies. J. Nucl. Med., 36: 215P, 1995.
18. Epstein, A., Marder, R., Winter, J., Stathopoulos, E., Chen, F., Parker, J., and Taylor, C. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
19. DeNardo, S., Peng, J., DeNardo, G., Mills, S., and Epstein, A. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Int. J. Radial. Appl. Instrum. Part B, 13: 303-310, 1986.
20. Kukis, D., DeNardo, G., DeNardo, S., Mirick, G., Miers, L., Greiner, D., and Meares, C. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res., 55: 878-884, 1995.
21. Kukis, D., Diril, H., Greiner, D., DeNardo, S., DeNardo, G., Salako, Q., and Meares, C. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer (Phila.), 73: 779-786, 1994.
22. DeNardo, G., DeNardo, S., Macey, D., and Macey, D. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: S. Srivastava (ed.). Radiolabeled Monoclonal Antibodies for Imaging and Therapy, pp. 293-310. New York: Plenum Publishing Corp., 1988.
23. Macey, D., DeNardo, G., and DeNardo, S. A treatment planning program for radioimmunotherapy. In: J. Vaeth (ed.), Frontiers of Radiation Therapy and Oncology, Vol. 24, pp. 123-131. Basel: S. Karger AG, 1990.
24. Eary, J., Appelbaum, F., Durack, L., and Brown, P. Preliminary validation of the opposing view method for quantitative gamma camera imaging. Med. Phys. (New York), 16: 382-387, 1989.
25. Thomas, S., Maxon, H., and Kereiakes, J. In vivo quantitation of lesion radioactivity using external counting methods. Med. Phys. (New York), 3: 253-255, 1976.
26. Sorenson, J. Deadtime characteristics of Anger cameras. J. Nucl. Med., 16: 284-288, 1975.
27. 131I-Lym-1 in patients with B-cell malignancies. Nucl. Med. Commun., 14: 587-595, 1993.
28. Loevinger, R., and Berman, M. A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides. MIRD Pamphlet No. 1. New York: Society of Nuclear Medicine, 1976.
29. 67Cu-2IT-BAT-Lym-1 for radioimmunotherapy. J. Nucl Med., 37: 146-150, 1996.
30. Snyder, W., Ford, M., Warner, G., and Watson, S. "S," Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and organs. MIRD Pamphlet No. 11. New York: Society of Nuclear Medicine, 1975.
31. Weber, D., Eckerman, K., Dillman, L., and Ryman, I. MIRD: Radionuclide Data and Decay Schemes, pp. 72-75. New York: Society of Nuclear Medicine, 1989.
32. Pretoris, H., Aswegen, A., Lotter, M., Herbst, C., Nel, M., and Otto, A. Verification of a varying threshold edge detection SPECT technique for spleen volume: a comparison with computed tomography volumes. J. Nucl. Med., 34: 963-967, 1993.
33. DeNardo, G., Maddock, S., Sgouros, G., Scheibe, P., and DeNardo, S. Immunoadsorption: an enhancement strategy for radioimmunotherapy. J. Nucl. Med., 34: 1020-1027, 1993.
34. DeNardo, G., Shen, S., DeNardo, S., Liao, S., Yu, S., and Macey, D. Validation of nuclear quantitation of tumor size and I-131 amount in an Alderson phantom by planar imaging. J. Nucl. Med., 33: 925, 1992.
35. Siegel, J., Wessels, B., Waston, E., Stabin, M., Vriesendorp, H., Bradley, E., Badger, C., Brill, A., Kwok, C., Stickney, D., Eckerman, K., Fisher, D., Buchsbaum, D., and Order, S. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antib. Immunoconjug. Radiopharm., 3: 213-233, 1990.
36. Macey, D., DeNardo, S., DeNardo, G., DeNardo, D., and Shen, S. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin. J. Nucl. Med., 20: 117-125, 1995.
37. SAS/STAT Users Guide. Version 6.08. Cary, NC: SAS Institute Inc., 1994.
38. Buyse, M., Staquet, M., and Sylvester, R. (eds.). Cancer Clinical Trials: Methods and Practice. New York: Oxford University Press 423-452, 1984.
39. Anderson, J. Analysis of survival by tumor response. J. Clin Oncol., 1: 710-719, 1983.
40. Kuzel, T., Rosen, S., Zimmer, A., Silverstein, E., Spies, S., Saletan, S., Norvitch, M., Birkhofer, M., Shochat, D., LoBuglio, A., Meredith, R., Khazaeli, M., Polansky, A., Hu, E., Chen, D., Lee, K., and Watkins, K. A Phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody Lym-1. Cancer Biother., 8: 3-16, 1993.
41. 131I-Lym-1 in patients with non-Hodgkin's lymphoma. Antib. Immunoconjug. Radiopharm., 6: 1-11, 1993.
42. Czuczman, M., Straus, D., Divgi, C., Graham, M., Garin-Chesa, P., Finn, R., Myers, J., Old, L., Larson, S., and Scheinberg, D. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J. Clin. Oncol., 11: 2021-2029, 1993.
43. Goldenberg, D. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131 labeled LL2 monoclonal antibody. J. Clin. Oncol., 11: 548-564, 1991.
44. 131I] anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
45. Press, O. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
46. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
47. Khazaeli, M., Conroy, R., and Lo Buglio, A. Human immune response to monoclonal antibodies. J. Immunol., 75: 42-52, 1994.
48. Baum, R., Nieson, A., Hertel, A., Nancy, A., Hess, H., Donnerstag, B., Sykes, T., Sykes, C., Suresh, M., Noujaim, A., and Hör, G. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer (Phila.), 73: 1121-1125, 1994.
49. Herlyn, D., Ross, A., and Koprowski, H. Anti-idiotype antibodies bear the internal image of a human tumor antigen. Science (Washington DC), 232: 100-102, 1986.
50. Herlyn, D., Zaloudik, J., Somasundaram, R., Jacob, L., Benden, A., and Mastangelo, M. Anti-idiotype vaccine in colorectal cancer patients. Hybridoma, 12: 515-520, 1993.